Neurocrine Biosciences (NBIX) Getting Somewhat Favorable Media Coverage, Report Shows
News headlines about Neurocrine Biosciences (NASDAQ:NBIX) have trended somewhat positive this week, Accern Sentiment Analysis reports. Accern identifies negative and positive press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Neurocrine Biosciences earned a daily sentiment score of 0.19 on Accern’s scale. Accern also assigned media stories about the company an impact score of 47.050309897851 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
These are some of the media stories that may have impacted Accern’s scoring:
- NBIX: Will File an NDA for Opicapone in 1H19 (finance.yahoo.com)
- Neurocrine Biosciences, Inc. (NBIX) to Post Q1 2018 Earnings of ($0.28) Per Share, Jefferies Group Forecasts (americanbankingnews.com)
- Q1 2018 Earnings Forecast for Neurocrine Biosciences, Inc. Issued By Oppenheimer (NBIX) (americanbankingnews.com)
- Jefferies Group Brokers Raise Earnings Estimates for Neurocrine Biosciences, Inc. (NBIX) (americanbankingnews.com)
- Oppenheimer Analysts Lift Earnings Estimates for Neurocrine Biosciences, Inc. (NBIX) (americanbankingnews.com)
Neurocrine Biosciences (NBIX) traded down $0.32 on Friday, reaching $85.25. The company had a trading volume of 855,438 shares, compared to its average volume of 1,030,000. The firm has a market capitalization of $7,520.00, a PE ratio of -52.30, a price-to-earnings-growth ratio of 280.14 and a beta of 0.26. Neurocrine Biosciences has a 52-week low of $39.21 and a 52-week high of $91.82. The company has a current ratio of 10.20, a quick ratio of 14.37 and a debt-to-equity ratio of 0.99.
Several analysts have recently commented on the company. Deutsche Bank raised their target price on Neurocrine Biosciences to $97.00 and gave the stock a “buy” rating in a research report on Wednesday. Barclays reaffirmed an “overweight” rating and issued a $100.00 target price on shares of Neurocrine Biosciences in a research report on Wednesday. JPMorgan Chase & Co. raised their target price on Neurocrine Biosciences from $79.00 to $100.00 and gave the stock an “overweight” rating in a research report on Wednesday. Oppenheimer set a $100.00 target price on Neurocrine Biosciences and gave the stock a “buy” rating in a research report on Wednesday. Finally, BidaskClub raised Neurocrine Biosciences from a “hold” rating to a “buy” rating in a research report on Thursday, January 4th. One investment analyst has rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company. Neurocrine Biosciences presently has an average rating of “Buy” and an average price target of $88.79.
In other Neurocrine Biosciences news, CEO Kevin Charles Gorman sold 105,983 shares of the business’s stock in a transaction dated Tuesday, February 6th. The stock was sold at an average price of $80.25, for a total value of $8,505,135.75. Following the completion of the sale, the chief executive officer now owns 339,482 shares of the company’s stock, valued at $27,243,430.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Dimitri E. Grigoriadis sold 86,368 shares of the business’s stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $78.32, for a total value of $6,764,341.76. Following the completion of the sale, the insider now directly owns 154,717 shares of the company’s stock, valued at approximately $12,117,435.44. The disclosure for this sale can be found here. In the last three months, insiders have sold 337,950 shares of company stock valued at $26,613,876. Insiders own 4.80% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This news story was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another website, it was stolen and reposted in violation of international copyright laws. The correct version of this news story can be read at https://www.thecerbatgem.com/2018/02/17/neurocrine-biosciences-nbix-getting-somewhat-favorable-media-coverage-report-shows.html.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.